ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

American Gene Technologies® Video Series “The Cure Chronicles” Wins BioBuzz Media Award

Rockville, Maryland, United States - 03-28-2023 (PR Distribution™) -


The Groundbreaking Series Features Engaging Conversations with People Living with HIV, Advocates and Medical Experts Striving Toward the Shared Goal of Ending HIV

Rockville, Maryland (March 28, 2023): “The Cure Chronicles,” an innovative video series launched by Maryland biotechnology company, American Gene Technologies, is the winner of the third annual BioBuzz Media Award. American Gene Technologies (AGT™) is developing gene therapy technology to combat HIV, and “The Cure Chronicles” takes a deep look into what it means to live with the disease. In the series, AGT’s CEO, Jeff Galvin, interviews HIV advocates and experts – including authors, comedians, doctors, community leaders, and filmmakers – most of whom are living with their own diagnoses. 

“We developed The Cure Chronicles because we wanted people to hear directly from those most impacted by HIV, as well as people who are making a difference in this space,” said Galvin. “Our hope is that this series helps break down the stigma that people often face when living with HIV.”

With nineteen episodes released to date, “The Cure Chronicles” features intimate conversations that touch on the many ways that people navigate their diagnosis – and the extraordinary paths it leads them on. Most have gone on to become advocates and educators about HIV, through comedy, film, social media, books, or by working directly with others who are living with HIV. The series also highlights medical experts that are at the forefront of HIV treatment and research. 

This approach is clearly resonating: the BioBuzz Media Award, which honors a media campaign that has “successfully engaged, informed, and connected people within scientific communities,” is a people’s choice award. According to BioBuzz, “This award honors a media campaign that most aligns with our own mission; ‘to create exceptional experiences that better connect people and employers and foster a stronger regional ecosystem.’”

Watch The Cure Chronicles here

About American Gene Technologies

American Gene Technologies is a gene therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people's lives through genetic medicines that rid the body of disease. Safety and durability data from American Gene Technologies’ Phase 1 HIV gene therapy clinical trial is published in the Frontiers in Medicine journal and a final report is being prepared for regulatory submission. In addition, the company has been granted four patents for the technology used to make AGT103-T and 11 patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. American Gene Technologies has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. The company’s treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2023.

American-Gene-Technologies-Video-Series-The-Cure-Chronicles-Wins-Bio-Buzz-Media-Award

Media Contact:
Kathy Fowler
American Gene Technologies
Phone: 410-963-2345
Email: kfowler@americangene.com

image widget

Media Contacts:

Company Name: American Gene Technologies
Full Name: Kathy Fowler
Phone: 410-963-2345
Email Address: Send Email
Website: https://www.americangene.com/

For the original news story, please visit https://www.prdistribution.com/news/american-gene-technologies-video-series-the-cure-chronicles-wins-biobuzz-media-award/9591485.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.